Roche signed a definitive agreement to acquire Poseida Therapeutics, a deal that includes Poseida’s portfolio of CAR T-cell therapy candidates being developed for multiple sclerosis (MS) and other diseases. Poseida and Roche have been collaborating since 2022 on cell therapies for people with blood cancer. The companies…
Roche
A test called Elecsys NfL — developed by Roche to measure blood levels of the nerve damage biomarker neurofilament light chain (NfL) in people with multiple sclerosis (MS) — has received breakthrough device designation in the U.S. That status, granted by the U.S. Food and Drug Administration (FDA),…
Roche has teamed up with researchers in Australia to study the immune and biological mechanisms leading to better outcomes for multiple sclerosis (MS) patients who are or have been pregnant. The four-year project, led by Vilija Jokubaitis, PhD, a neuroscientist and group leader at Monash University, is expected…
Two years of treatment with Ocrevus (ocrelizumab) outperformed Rebif (interferon beta-1a) at preventing myelin loss in people with relapsing multiple sclerosis (MS), according to a new analysis of data from the OPERA II clinical trial. Ocrevus’ protection against demyelination was observed both in MS lesions,…
Nearly three of every four participants in the CONSONANCE clinical trial, which is evaluating Ocrevus (ocrelizumab) in people with primary or secondary progressive multiple sclerosis (MS), showed no evidence of disease progression after a year of treatment. That’s according to new data presented at the American Academy of…
Roche is teaming up with the University of Plymouth in the U.K. to help develop Floodlight MS, the company’s app to monitor multiple sclerosis (MS). “We were pleased to collaborate with Roche on an innovative project to validate the Floodlight MS app and, as with everything we do…
The U.S. Food and Drug Administration (FDA) has agreed to review TG Therapeutics’ application seeking the approval of ublituximab as a treatment for people with relapsing forms of multiple sclerosis. An FDA’s decision is expected on or before Sept. 28. The agency is not currently planning to hold an…
Temedica, a Munich-based digital health company, has joined efforts with Roche to launch a free mobile app that aims to improve care for people with multiple sclerosis (MS) living in Germany. Available in German only, the Brisa app will make a record of individual disease progression in…
A smartphone-based app called Floodlight can reliably assess cognition, arm and hand function, and walking abilities in people with multiple sclerosis (MS), according to new analyses. “Detection of progression onset or worsening is critical to optimally adapt the therapeutic strategy” patients are using to treat the neurodegenerative disease,…
A Phase 3 clinical trial testing the effect of Ocrevus (ocrelizumab) on upper limb disability progression in people with primary progressive multiple sclerosis (PPMS) is recruiting participants. The trial, called O’HAND (NCT04035005), expects to enroll approximately 1,000 adults with PPMS, ages 18 to 65, at more than…
Treatment with anti-CD20 antibodies reduced the loss of myelin and improved the survival of neurons in a rat model of multiple sclerosis (MS), a new study reports. The findings imply that B-cells — the immune cells that are killed by anti-CD20 antibodies — play a central role in the…
Two global Phase 3 clinical trials comparing fenebrutinib, an investigational oral BTK inhibitor by Roche, with Aubagio (teriflunomide) are now enrolling adults with relapsing forms of multiple sclerosis (MS), the National MS Society announced in a press release. The twin studies, called FENhance 1 (NCT04586023)…
Editor’s note: The Multiple Sclerosis News Today team is providing in-depth coverage of the 2021 Virtual AAN Annual Meeting, April 17–22. Go here to read the latest stories from the conference. Treating multiple sclerosis (MS) in its earlier stages with Ocrevus (ocrelizumab) can substantially lower disease activity and lessen damage…
Treatment with rituximab before or during pregnancy was not associated with major pregnancy or infant complications, according to a case series of 19 women with multiple sclerosis (MS) and other autoimmune diseases. These findings add to the limited available evidence on the use of rituximab by expectant mothers either…
The U.S. Food and Drug Administration has approved a shorter infusion time of Ocrevus (ocrelizumab) for treating relapsing or primary progressive multiple sclerosis (MS). Infusion refers to the slow delivery of a therapy directly into the bloodstream over a period of time. The decision shortens the twice-yearly infusion…
Early and continuous use of Ocrevus (ocrelizumab) significantly slows disability progression and delays the time until wheelchair reliance in people with primary progressive multiple sclerosis (PPMS), new Phase 3 data spanning more than six years show. Findings from the ORATORIO trial, comparing immediate use with a two-year delay, support Ocrevus’ sustained…
Among oral sphingosine-1-phosphate (S1P) receptor modulators for multiple sclerosis (MS), Novartis’s Gilenya (fingolimod) remains physicians’ favorite in the U.S., but prescriptions of recently-launched Bristol Myers Squibb’s Zeposia (ozanimod) are beginning to rise, according to a survey conducted by Spherix Global Insights. Also, COVID-19 not…
Early use of Ocrevus (ocrelizumab) significantly slows shrinkage of the thalamus — a brain region involved in sensory and motor functions — in people with relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS), according to new analyses from three Phase 3 trials that compared immediate use with a two-year…
Roche has launched a Phase 3 clinical trial program to evaluate fenebrutinib, its investigational oral BTK inhibitor, in people with relapsing forms of multiple sclerosis (MS) and primary progressive MS (PPMS). Data on fenebrutinib’s potency and selectivity, as well as the design of the clinical…
Switching to Genentech’s Ocrevus (ocrelizumab) following suboptimal treatment responses significantly lessens symptoms and leads to high rates of no evidence of disease activity in people with relapsing-remitting multiple sclerosis (RRMS), according to data from a Phase 3b clinical trial. That finding, as well as data about patients’ adherence and…
Ocrevus (ocrelizumab), a second-generation anti-CD20 antibody, may be associated with a greater risk of infections. But it carries a lower risk of cancer and immune reactions than first-generation rituximab in people with multiple sclerosis (MS), according to a real-life study. The higher incidence of infections linked with Ocrevus’…
Rituximab is more effective and leads to fewer treatment discontinuations in people with multiple sclerosis (MS) than Gilenya (fingolimod) and Tecfidera (dimethyl fumarate), according to real-world data based on two years of therapy. Rituximab’s effectiveness appeared to be comparable to that of Tysabri (natalizumab), but with fewer…
To speed research and work on more personalized treatments for serious diseases, Roche and its subsidiary Genentech announced a partnership with PicnicHealth to access its collection of real-world data. Eligible adults with MS in the United States are also being invited to join a multiyear study assembling such…
The European Medicines Agency (EMA) approved a shorter infusion time for Ocrevus (ocrelizumab), an approved treatment for people with relapsing or primary progressive multiple sclerosis (MS). The approval follows a positive recommendation from EMA’s Committee for Medicinal Products for Human Use (CHMP),…
For a comprehensive support app developed for multiple sclerosis (MS) patients, RxMx and Roche have won the Patient Engagement Innovation Award from Medtech Breakthrough. The fourth annual awards program recognized top health and medical technology products and companies. Healthcare company RxMx and pharmaceutical company Roche collaborated to produce…
People with multiple sclerosis (MS) may not be at higher risk of developing a severe COVID-19 infection, according to preliminary data from patients in Italy. “At the moment, these results seem to be quite reassuring for most people with MS,” Marco Salvetti, MD, PhD, professor at Sapienza…
COVID-19 infection in a multiple sclerosis (MS) patient being treated with Ocrevus (ocrelizumab) — an immunosuppressive therapy — was not associated with any serious complications, a case study reports. This finding supports current suggestions that immunosuppressive therapies, by dampening immune and inflammatory responses, may help to protect…
Starting treatment with Ocrevus early can lower almost by half the need for a walking aid in people with relapsing forms of multiple sclerosis (MS) over six years, new analyses of Phase 3 trial data that compared immediate initiation with a two-year delay show. A separate analysis also found…
The U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) have accepted applications from Genentech to shorten the infusion time for Ocrevus, an approved treatment for multiple sclerosis. If approved, the time to administer Ocrevus will be shortened to a two-hour session, instead…
Prescriptions of Roche’s Ocrevus (ocrelizumab) among multiple sclerosis (MS) patients initiating or switching a disease-modifying therapy (DMT) continue to rise in Europe, according to a survey conducted by Spherix Global Insights. Ocrevus, an anti-CD20 monoclonal antibody administered directly into a vein, was approved in the European Union to treat active forms…